Newswise — Today Siemens Healthcare Diagnostics reveals its latest in vitro diagnostic solu-tions—including the recently FDA-cleared ADVIA Centaur XPT Immunoassay Sys-tem1—at the 2015 AACC Annual Meeting and Clinical Lab Expo, Atlanta, July 26–30. In addition to featuring its portfolio of multidisciplinary solutions designed for use in hospital, reference, and physician office laboratories and near patients’ bedsides, the booth will highlight how Siemens’ customers around the world are achieving their clinical and workflow goals.
“Customers need a reliable partner who can help them achieve higher levels of op-erational efficiency while providing quality results that lead to optimal patient care,” said Michael Reitermann, CEO, Siemens Healthcare Diagnostics. “The solutions we are showcasing at this year’s AACC can help customers successfully achieve their workflow and clinical goals, regardless of the size of their operations or testing de-mands.”
One such example, the ADVIA Centaur XPT Immunoassay System (1), is a high-throughput analyzer that enhances workflow to meet the demands for reliable and rapid immunoassay testing. Recently FDA-cleared, this analyzer is designed to pro-vide simple, continuous operation; accurate, timely results; and powerful, seamless connectivity including to Aptio Automation, the company’s flexible, track-based automation system.
Aptio Automation’s connectivity options include the ADVIA Chemistry XPT System, Siemens’ newest high throughput chemistry analyzer, and the Sysmex CS-5100 System (2), a high-volume hemostasis analyzer. Siemens is the only single-source provider able to connect all four key laboratory disciplines—chemistry, immunoas-say, hematology, and hemostasis—to the automation track.
Also at the booth is the Sysmex CS-2100i System (2), a mid-volume benchtop hemo-stasis analyzer. Both the Sysmex CS-2100i System and Sysmex CS 5100 System are currently under FDA review and utilize simultaneous multi wavelength detection and first-to-market PSI technology to manage unsuitable coagulation samples (e.g., improperly filled sample tubes) for high-quality accurate results.
Another new hemostasis offering on display—one for point-of-care testing—is the Xprecia Stride Coagulation Analyzer (1). Winner of the prestigious Red Dot design award, this handheld coagulation system is designed to perform prothrombin time testing (PT/INR). In hematology, the company now offers small to mid-sized labora-tories the ADVIA 360 Hematology System (3), ADVIA 560 Hematology System (3), and ADVIA 560 AL Hematology System (3), each of which became available globally earlier this year. These systems offer state-of-the-art hematology testing capabilities and may be used as backup systems for larger laboratories.
The company’s leadership in workflow and clinical excellence is also evidenced by its latest products in urinalysis, infectious disease and molecular testing, and custom-er education.
The CLINITEK AUWi PRO Automated Urinalysis System (4) is a true walkaway solution for integrated urinalysis testing. It combines a urine chemistry analyzer (CLINITEK Novus Automated Urine Chemistry Analyzer) with a urine sediment ana-lyzer (Sysmex UF-1000i Automated Urine Particle Analyzer).
New infectious disease assays include the ADVIA Centaur HIV Ag/Ab Combo (CHIV) assay, which allows for sensitive and specific detection of HIV p24 antigen and antibodies and may improve detection of early acute infections. The ADVIA Centaur Syphilis assay is used as an aid in the disease’s diagnosis. This assay al-lows for sensitive and specific detection of antibodies to Treponema pallidum in hu-man serum or plasma (EDTA, lithium or sodium heparinized, sodium citrate).
In molecular testing, experts will be on hand to discuss the Siemens Tissue Prepa-ration Solution, a single fully-automated solution and reproducible and standardized process for the extraction of high-quality nucleic acid from formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissues. This solution is enabling technology for the next generation of molecular diagnostics, including next-generation sequenc-ing for infectious disease and oncology testing.
Another innovative offering making its debut at AACC is Siemens PEPconnect, part of the total Personalized Education Plan (PEP) (5), the industry’s first personalized ed-ucation and performance experience for the healthcare professional. With optimized technology and increased search capabilities, PEPconnect allows customers to ac-cess education and real-time performance support virtually anytime, anywhere, and on any device, including PCs, laptops, tablets, and smartphones. It enables users to construct a personalized learning experience and easily share and connect with oth-ers in their workgroup community.
For more information about Siemens at AACC, including the company’s sponsored educational workshops on chronic kidney disease and Centers for Disease Control (CDC) recommendations for syphilis and hepatitis C testing, scientific posters, and in-booth clinical presentations, please visit www.siemens.com/aacc.
1. Not available for sale in the U.S. Product availability varies by country.2. Under FDA review. Not available for sale in the U.S.3. Not all parameters are available in the U.S. Product availability varies by country.4. Available in the U.S., Canada, and Puerto Rico.5. Patent pending.
Contact for journalists:Siemens Healthcare, Media and Public Relations
Follow us on Twitter at www.twitter.com/siemenshealth.
The products/features (here mentioned) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Further details are available from the local Siemens organizations.
Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering ex-cellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world's largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in off-shore wind turbine construction, a leading supplier of combined cycle turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as auto-mation, drive and software solutions for industry. The company is also a leading provider of medical im-aging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2014, which ended on September 30, 2014, Siemens generated revenue from continuing operations of €71.9 billion and net income of €5.5 billion. At the end of September 2014, the company had around 343,000 employees worldwide on a continuing basis. Further information is available on the Internet at http://www.siemens.com.
RSS